Dyne Therapeutics, Inc. (DYN)

USD 24.56

(-6.12%)

Market Cap (In USD)

2.49 Billion

Revenue (In USD)

-

Net Income (In USD)

-235.93 Million

Avg. Volume

1.35 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
11.93-47.45
PE
-
EPS
-
Beta Value
1.095
ISIN
US26818M1080
CUSIP
26818M108
CIK
1818794
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. John G. Cox M.B.A.
Employee Count
-
Website
https://www.dyne-tx.com
Ipo Date
2020-09-17
Details
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..